UK markets close in 2 hours 18 minutes

Lexicon Pharmaceuticals, Inc. (LXRX)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
1.6500+0.1100 (+7.14%)
At close: 04:00PM EDT
1.7300 +0.08 (+4.85%)
Pre-market: 09:12AM EDT
Currency in USD

Valuation measures4

Market cap (intra-day) 403.83M
Enterprise value 339.87M
Trailing P/E 3.74
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)301.21
Price/book (mrq)4.34
Enterprise value/revenue 282.28
Enterprise value/EBITDA -2.08

Trading information

Stock price history

Beta (5Y monthly) 1.27
52-week change 3-46.43%
S&P500 52-week change 323.57%
52-week high 33.7900
52-week low 30.9200
50-day moving average 32.1354
200-day moving average 31.6792

Share statistics

Avg vol (3-month) 34.57M
Avg vol (10-day) 33.19M
Shares outstanding 5246.24M
Implied shares outstanding 6246.24M
Float 899.98M
% held by insiders 11.69%
% held by institutions 182.18%
Shares short (15 Apr 2024) 420.12M
Short ratio (15 Apr 2024) 46.39
Short % of float (15 Apr 2024) 442.17%
Short % of shares outstanding (15 Apr 2024) 48.17%
Shares short (prior month 15 Mar 2024) 421.35M

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 21:7
Last split date 321 May 2015

Financial highlights

Fiscal year

Fiscal year ends 31 Dec 2023
Most-recent quarter (mrq)31 Dec 2023

Profitability

Profit margin 0.00%
Operating margin (ttm)-6,657.69%

Management effectiveness

Return on assets (ttm)-50.67%
Return on equity (ttm)-168.50%

Income statement

Revenue (ttm)1.2M
Revenue per share (ttm)0.00
Quarterly revenue growth (yoy)2,407.10%
Gross profit (ttm)N/A
EBITDA -171.2M
Net income avi to common (ttm)-177.12M
Diluted EPS (ttm)-0.8000
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)170.03M
Total cash per share (mrq)0.69
Total debt (mrq)106.06M
Total debt/equity (mrq)113.91%
Current ratio (mrq)5.60
Book value per share (mrq)0.38

Cash flow statement

Operating cash flow (ttm)-161.9M
Levered free cash flow (ttm)-94.97M